Eiger BioPharmaceuticals (EIGR) Receives EMA Orphan Designation for Exendin 9-39 as NIPHS Treatment

October 17, 2016 8:07 AM EDT
Get Alerts EIGR Hot Sheet
Trade EIGR Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced that the European Medicines Agency (EMA) has granted orphan designation to exendin 9-39 for the treatment of non-insulinoma pancreatogenous hypoglycemia syndrome (NIPHS). NIPHS describes a spectrum of acquired metabolic disorders characterized by inappropriately high insulin levels (hyperinsulinemia) and low blood glucose levels (hypoglycemia), which includes post-bariatric hypoglycemia (PBH). Eiger is developing a novel subcutaneously administered form of exendin 9-39 for patients who experience dangerously low postprandial (postmeal) blood glucose levels due to PBH, a rare and debilitating disorder with no approved treatment.

"Stanford researchers have demonstrated activity in two separate clinical proof-of-concept studies, first using an intravenous infusion of exendin 9-39 and more recently using subcutaneous injection of exendin 9-39 in patients with PBH. Exendin 9-39 prevented hypoglycemia and associated symptoms during oral glucose tolerance testing in patients with PBH," said David Cory, President and CEO of Eiger. "A significant unmet medical need exists and exendin 9-39 represents the first potential targeted therapy for patients suffering from PBH. A phase 2 multiple ascending dose (MAD) study of subcutaneously injected exendin 9-39 in PBH patients is currently enrolling at Stanford and we look forward to reporting results."

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News

Add Your Comment